Part of Springer Nature

Artery Research

Volume 20, Issue C, December 2017, Pages 49 - 49

NAA1 NICOTINAMIDE RIBOSIDE SUPPLEMENTATION REDUCES AORTIC STIFFNESS AND BLOOD PRESSURE IN MIDDLE-AGED AND OLDER ADULTS

Authors
Christopher Martens1, Blair Denman1, Melissa Mazzo1, Michael Armstrong2, Nichole Reisdorph2, Matthew McQueen1, Michel Chonchol3, Douglas Seals1
1Department of Integrative Physiology, University of Colorado Boulder, Boulder, CO, USA
2Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Denver, CO, USA
3Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, Denver, CO, USA
Available Online 6 December 2017.
DOI
https://doi.org/10.1016/j.artres.2017.10.021How to use a DOI?
Abstract

Purpose: Regular calorie restriction (CR) improves endothelial function and lowers aortic stiffness in older mice and humans; however, adherence to sustained CR remains poor, and possibly unsafe in normal weight older adults. Nicotinamide adenine dinucleotide (NAD+) is an important signaling molecule involved in the beneficial effects of CR and we have recently demonstrated that boosting NAD+ reverses these measures of arterial aging in older mice. The purpose of this study was to determine if supplementation with nicotinamide riboside (NIAGEN®; ChromaDex, Inc.), a naturally occurring precursor to NAD+, would similarly improve vascular function with aging in humans.

Methods: Healthy middle-aged and older adults (65 ± 2 yrs, n = 24) received oral NIAGEN® (500 mg, 2x/day) and placebo capsules for six weeks each in a randomized, placebo-controlled crossover study. Blood pressure (BP), aortic stiffness (carotid-femoral pulse wave velocity [PWV]), and endothelial function, (brachial artery flow-mediated dilation [FMD]), were measured at the end of each intervention phase.

Results: NIAGEN® safely and effectively raised circulating levels of NAD+ and related metabolites. Although no effect was observed on endothelial function, NIAGEN® significantly lowered PWV as well as systolic (SBP) and diastolic blood pressure (DBP) in all subjects (P < 0.05). When separated by baseline BP status, the BP-lowering effect of NIAGEN® was observed in pre-hypertensive (pHTN, n = 13) but not normotensive (N = 11) individuals (P < 0.01). Interestingly, NIAGEN® was lowered in all subjects regardless of baseline BP status.

Conclusion: Chronic NIAGEN® supplementation lowers SBP in pHTN older adults and reduces aortic stiffness, independent of baseline blood pressure status.

Open Access
This is an open access article distributed under the CC BY-NC license.

Download article (PDF)
View full text (HTML)

Journal
Artery Research
Volume-Issue
20 - C
Pages
49 - 49
Publication Date
2017/12
ISSN (Online)
1876-4401
ISSN (Print)
1872-9312
DOI
https://doi.org/10.1016/j.artres.2017.10.021How to use a DOI?
Open Access
This is an open access article distributed under the CC BY-NC license.

Cite this article

TY  - JOUR
AU  - Christopher Martens
AU  - Blair Denman
AU  - Melissa Mazzo
AU  - Michael Armstrong
AU  - Nichole Reisdorph
AU  - Matthew McQueen
AU  - Michel Chonchol
AU  - Douglas Seals
PY  - 2017
DA  - 2017/12
TI  - NAA1 NICOTINAMIDE RIBOSIDE SUPPLEMENTATION REDUCES AORTIC STIFFNESS AND BLOOD PRESSURE IN MIDDLE-AGED AND OLDER ADULTS
JO  - Artery Research
SP  - 49
EP  - 49
VL  - 20
IS  - C
SN  - 1876-4401
UR  - https://doi.org/10.1016/j.artres.2017.10.021
DO  - https://doi.org/10.1016/j.artres.2017.10.021
ID  - Martens2017
ER  -